Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03967223 · ClinicalTrials.gov registry record · Phase 2
Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Solid Tumors
A Phase 2 study of Neoplasms, sponsored by Uswm CT.
- Active
- Registry status
- Phase 2
- Development phase
- 103
- Enrollment target
- 20
- Study locations
NCT03967223 is a Phase 2 study of Neoplasms that is active but no longer recruiting, run by Uswm CT. The registered enrollment target is 103 participants, below the 1,621-participant average among 158 other Neoplasms trials with a reported enrollment target (94% lower). The trial reports 20 study locations across 16 states.
The verdict
NCT03967223, a Phase 2 study of Neoplasms, is active but no longer recruiting, sponsored by Uswm CT.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 103 participants
- Enrollment target
- 20
- Study locations
Study Summary
This trial will evaluate safety and efficacy of human engineered T-cell therapies, in participants with advanced tumors.
Conditions Studied
Interventions
- DRUG Cyclophosphamide
- DRUG Fludarabine
- DRUG Letetresgene autoleucel (lete-cel, GSK3377794)
Study Locations (20)
California
- City of Hope National Medical Center - Duarte
- Stanford Hospital and Clinics - Stanford
Massachusetts
- Dana Farber Cancer Institute - Boston
- Massachusetts General Hospital - Boston
Minnesota
- Minnesota Oncology Hematology - Minneapolis
- Mayo Clinic Rochester - Rochester
Texas
- University Of Texas Southwestern Medical Center - Dallas
- University of Texas Southwestern Medical Center - Dallas
Colorado
- Sarah Cannon Research Institute - Denver
Florida
- Mayo Clinic Jacksonville - Jacksonville
Illinois
- University of Chicago - Chicago
Iowa
- University of Iowa College of Medicine - Iowa City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 103 participants |
| Start Date | 2019-12-31 |
| Est. Completion | 2026-07-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03967223
The ClinicalTrials.gov registry entry for NCT03967223 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 103 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,621-participant average among 158 other Neoplasms trials with a reported enrollment target (94% lower). The listed sponsor is Uswm CT, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Neoplasms appearing as the primary indexed condition, and to 3 interventions - of which Cyclophosphamide is the first listed.
NCT03967223 reports 20 study locations spanning 16 distinct geographic areas - top geographies include California, Massachusetts, Minnesota.
Frequently Asked Questions
What is clinical trial NCT03967223 about?
NCT03967223 is a clinical study titled "Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Solid Tumors". This trial will evaluate safety and efficacy of human engineered T-cell therapies, in participants with advanced tumors.
What is the current status of trial NCT03967223?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 103 participants. The study started on 2019-12-31. Estimated completion is 2026-07-31.
What conditions does trial NCT03967223 study?
This clinical trial studies the following conditions: Neoplasms.
What interventions are being tested in trial NCT03967223?
The interventions under investigation include: Cyclophosphamide (DRUG), Fludarabine (DRUG), Letetresgene autoleucel (lete-cel, GSK3377794) (DRUG).
Who is sponsoring clinical trial NCT03967223?
This trial is sponsored by Uswm CT, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03967223 being conducted?
This trial has 20 study locations across California, Colorado, Florida, Illinois, Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of AdAPT-001 in Subjects With Sarcoma and Refractory Solid Tumors
RECRUITING · Phase 2
-
A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer
RECRUITING · Phase 2
-
Take the Reins: The Effects of Nutrient Timing on Cancer-related Fatigue
RECRUITING · Phase 2
-
A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer
RECRUITING · Phase 2
-
Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells
RECRUITING · Phase 2
-
Rapid Analysis and Response Evaluation of Combination Anti-Neoplastic Agents in Rare Tumors (RARE CANCER) Trial: RARE 1 Nilotinib and Paclitaxel
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.